ilShinbiobase KRX:068330KOSDAQ
일신바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days2
Articles tracked1since Sep 11
In Q2 2026, ilShinbiobase reported revenue of ₩4.2bn, up 17.8% year on year, and operating profit of ₩1.5bn. ilShinbiobase (일신바이오) appeared in 1 Korean news article and 2 DART filings over the past seven days. Coverage peaked on Oct 2 with 1 article. The most common catalyst was contracts & orders (1).
Filing signals Supply contract Screener
ilShinbiobase quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.2bn | +17.8% | ₩1.5bn margin 36.6% | ₩1.6bn |
| Q1 2026 | ₩2.5bn | +33.5% | ₩454m margin 18.0% | ₩975m |
| Q4 2025 derived | ₩4.2bn | +9.0% | ₩1.1bn margin 25.4% | ₩1.5bn |
| Q3 2025 | ₩4.9bn | +85.6% | ₩1.9bn margin 39.2% | ₩1.9bn |
| Q2 2025 | ₩3.5bn | +28.1% | ₩1.1bn margin 31.6% | ₩742m |
| Q1 2025 | ₩1.9bn | +22.1% | ₩443m margin 23.5% | ₩662m |
| Q4 2024 derived | ₩3.9bn | -1.7% | ₩1.2bn margin 29.8% | ₩1.9bn |
| Q3 2024 | ₩2.6bn | +15.4% | ₩375m margin 14.3% | ₩528m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
ilShinbiobase top stories 2 weeks, by number of outlets
- 1